Vivek Ramaswamy Quotes

There's always going to be the need for new medications, better medications.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

And there are lots of drug companies that are working on cure or medicine.

I had seen a Pfizer's pilot plant in 1965 and decided that, 'I'll build a Pfizer.' If not Pfizer, I have built Dr Reddy's, which is no less respectable.

To start with, pharma was an industry based on innovation, drug discovery.

My choice of learning pharmacy was driven by my interests, curiosity, and a desire to seek new medicines for patients.

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

I fell in love with the science at Merck.

On the third stage is used for medicine, it is not known to the public.

I keep encouraging the pharmaceutical companies to put more money into R&D.

Analytical pharmacology has got an important and exciting future.

Pharmacology is benefited by the prepared mind. You need to know what you are looking for.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.

I was criticized for saying that Pfizer doesn't know how to make a molecule right.

In research, I wanted to establish the medicinal chemistry/bioassay conjugation as an academic pursuit, as exciting to the imagination as astrophysics or molecular biology.

Aspen's investment in TesoRx will assist in the work being undertaken to bring this product to market and in investing behind TesoRx's pipeline and technology that has the potential to be used for a wide range of different applications.

Drug discovery is terribly expensive, just to find out how one drug could or could not work and all its side effects.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

I want to make a drug. I want the science to be more than imaginary, where I think, 'We're learning these fundamental principles, blah, blah, blah, blah, blah.' I think we are doing that, but I want to do something really practical. I want to actually, in my lifetime, help people.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

All I ever promised was that I was sure I could develop a new pharmacological agent which might answer a physiological question. Any utility would be implicit in that answer.

I am very passionate about India's place in bio-pharmaceuticals, and that is what I really want to drive and create leadership for in India because I really think it is possible.

I would say that the pharmaceutical industry is hyper-competitive from a global perspective.

When you work in the pharmaceutical industry you realize that there's a lot out of people's control, and there's ways that people can be helped.